Compare JBSS & SPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JBSS | SPTX |
|---|---|---|
| Founded | 1959 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 1994 | 2026 |
| Metric | JBSS | SPTX |
|---|---|---|
| Price | $86.88 | $24.19 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $109.00 | N/A |
| AVG Volume (30 Days) | ★ 116.7K | 95.6K |
| Earning Date | 04-29-2026 | N/A |
| Dividend Yield | ★ 3.26% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.55 | N/A |
| Revenue | ★ $1,107,246,000.00 | N/A |
| Revenue This Year | $5.58 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.05 | ★ N/A |
| Revenue Growth | ★ 3.79 | N/A |
| 52 Week Low | $59.07 | $17.59 |
| 52 Week High | $92.08 | $24.65 |
| Indicator | JBSS | SPTX |
|---|---|---|
| Relative Strength Index (RSI) | 59.52 | 67.88 |
| Support Level | $73.95 | $18.72 |
| Resistance Level | $87.16 | N/A |
| Average True Range (ATR) | 2.16 | 1.27 |
| MACD | 0.29 | 0.25 |
| Stochastic Oscillator | 90.81 | 92.63 |
John B Sanfilippo & Son Inc is one of the processors and distributors of peanuts, pecans, cashews, walnuts, almonds, and other nuts in the United States. These nuts are sold under a variety of private brands and the Fisher, Orchard Valley Harvest, and Sunshine Country brand names. It also markets and distributes, and in the majority of cases, manufactures or processes, a diverse product line of food and snack products, including peanut butter, almond butter, cashew butter, candy and confections, snacks and trail mixes, snack bites, sunflower kernels, dried fruit, corn snacks, sesame sticks and other sesame snack products under private brands and brand names.
Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.